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The inspiratory partial pressure of oxygen (PIO2) at
sea level is approximately 160 mm Hg. At altitudes of
2000 and 4500 m above sea level, the PIO2 is about 120
and 85 mm Hg, respectively. Concomitantly, in the alve-
olar air, PO2 is reduced to 75 and 55 mm Hg. In the
healthy individual, the resulting hypoxemia causes a vari-
ety of respiratory, circulatory, and electrocardiographic
(ECG) changes,1 including an increase in sympathetic
tone, with pulmonary hypertension, hyperventilation, and
an enhanced diuresis. The ECG changes have mainly
been attributed to the synergistic effects of catecholamine
secretion and vagal withdrawal rather than to direct
hypoxic effects.2 In patients with marginal cardiocircula-
tory reserve or coronary artery disease (CAD), these
effects may cause cardiac decompensation3 and silent
ischemia during normal daily activities, even at a modest
altitude of 2000 m.4 Thus it is current clinical practice to
advise patients with CAD not to exceed moderate alti-
tudes of about 2000 to 2500 m.5-7 Similar conditions are
encountered in most airplanes during flight, raising some
concerns about the risk of air travel for patients with
CAD.8,9
In experimental animals, acute hypoxemia10 and
chronic hypoxemia have been shown to increase base-
line11 and maximal drug-induced12 and exercise-
induced11 myocardial blood flow (MBF). In contrast,
only a few studies have examined the influence of acute
hypoxic hypoxia on coronary circulation in human
beings. A close relation between cardiac effort, myocar-
dial oxygen consumption, and coronary flow has been
repeatedly reported.13-15 Four decades ago, Gregg16 was
the first to point out that most of the oxygen is normally
removed from the coronary blood so that the oxygen con-
tent of coronary sinus (venous) blood cannot be reduced
by very much. Therefore increased oxygen delivery must
be achieved primarily by increased MBF. In fact, MBF is
regulated to maintain constant myocardial tissue oxygen
tension.17 However, Kaijser et al18 found an enhanced
oxygen extraction at rest during acute exposure to an alti-
tude of 2300 m and no change in MBF, which increased
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during physical exercise. Thus it remains unclear whether
a reduced coronary vasodilator capacity (such as that in
patients with CAD) represents a risk factor during acute
exposure to hypoxia.
The purpose of this study was to assess the influence
of different stages of acute hypoxic hypoxia on MBF in
healthy human volunteers.
METHODS
The study protocol was approved by the local ethics com-
mittee. Each volunteer gave informed written consent after the
investigative nature of the study and its risks and merits had
been carefully explained.
Study Population
We studied 8 healthy volunteers (1 woman and 7 men,
aged 26 ± 3 years [mean ± SD], range 23-32 years) who were
nonacclimated (ie, they had no sojourn at or above 2700 m 4
weeks before the experiment and were all living at altitude of
Zurich, Switzerland). None of the subjects had a history of car-
diovascular disease or smoking. Further inclusion criteria were
normal heart rate, blood pressure, and electrocardiography and
low probability of CAD development.19
Study Protocol and Radiopharmaceuticals 
The simulation of altitude hypoxia (hypoxic hypoxia) was
achieved by inhalation of moistened hypoxic gas mixtures
(through a mouthpiece), consisting of approximately 17.5%
and 12.5% oxygen in nitrogen, which correspond to altitudes
of 2000 and 4500 m, respectively. The 2 periods of hypoxic
breathing were interposed by normoxic resting ventilation for
15 minutes. Heart rate and peripheral arterial oxygen satura-
tion (SaO2) were recorded with a finger pulse oximeter
(Nellcor N-200E; Nellcor Inc, Hayward, Calif). Arterial blood
pressure was measured by the oscillometric Riva-Rocci
method with an upper arm cuff (Bosotron 2; Bosch & Sohn,
Jungingen, Germany). End-tidal partial pressure of carbon
dioxide (PEtCO2) and respiratory frequency were determined
with a capnograph (Dräger Capnodig; Dräger, Lübeck,
Germany). 
At baseline 1 (450 m, Zurich), all volunteers breathed
through a mouthpiece with occluded nasal airways to avoid con-
founding errors due to irritation by this installation. After a car-
diorespiratory steady state was achieved, as assessed by a steady
PEtCO2, SaO2, and heart rate, positron emission tomography
(PET) measurements were performed after 15 minutes at base-
line 1, 2000 m, and 4500 m and at the end of the experiment at
baseline 2 (450 m, Zurich). By use of a bolus technique, 800
MBq of O-15–labeled water ([15O]H2O) was injected into a
peripheral vein of each volunteer at all of the above-mentioned
conditions, while acquisition of the serial transaxial tomo-
graphic images of the heart was started. The 20 minutes between
each [15O]H2O injection allowed ample time for [15O] decay to
occur (halftime = 2 minutes). After the second baseline mea-
surement, 350 MBq of [13N]ammonia was injected for visual-
ization of the myocardium to draw the regions of interest (ROIs)
for quantitative analysis. Patient positioning for each image set
was aided by marking the patient’s chest with a felt-tip pen and
aligning the marks with the reference laser beam of the tomo-
graph.
PET Protocol
All images were acquired on a GE positron emission tomo-
graph (GE Medical Systems, Milwaukee, Wis). This device
records 35 image planes simultaneously. The axial field of view
is 14.5 cm. A 30-minute blank scan was recorded as part of the
daily routine procedures. Correct positioning of the volunteer’s
heart within the axial field of view of the tomograph was ascer-
tained on a 4-minute rectilinear transmission scan. This was fol-
lowed by a 20-minute transmission scan for photon attenuation
correction. Beginning with the intravenous administration of
[15O]H2O, twelve 10-second frames, four 30-second frames, and
one 60-second frame were recorded. Twelve-lead electrocardio-
grams were monitored continuously throughout the study. Heart
rate and blood pressure were recorded at 1- and 5-minute inter-
vals, respectively.
Data Analysis
Two representative midventricular slices were chosen
from the acquired sets of 35 transaxial images for quantita-
tive analysis. The images acquired after the ammonia injec-
tion were used to define a septal, anterior, and lateral ROI of
the myocardial territory.20 Furthermore, a spheric ROI was
placed in the blood pool of the left ventricle. All ROIs were
then pasted to the dynamically acquired image sets.
Myocardial and blood pool time-activity curves were gener-
ated from the dynamic frames and corrected for radioisotope
decay.
Estimates of MBF
MBF was estimated by model fitting of the blood pool
and myocardial time-activity curves. The PET-measured time-
activity curves were fitted with a 1-compartment model.21
MBF values for each ROI were calculated and averaged in
each patient to create a mean MBF value for the entire
myocardium. Because resting MBF is determined by cardiac
workload,22 we also considered baseline MBF normalized for
the rate pressure product (RPP),23 an index of myocardial oxy-
gen consumption, by dividing MBF by RPP × 10–4 at each
study condition for each patient.
Statistical Analysis
Values are given as mean ± SD, unless stated otherwise.
Comparisons of hemodynamic and MBF values between the
different study conditions were performed with analysis of vari-
ance statistics for repeated measures. If the P value was below
.05, the Scheffé test was applied. 
RESULTS
All subjects tolerated the simulated ascent to high
altitude subjectively well and without major objective
impairment. 
Hemodynamic and ECG Findings
Heart rate was similar at baseline 1 (68 ± 7 beats/min)
and 2000 m (68 ± 9 beats/min), increased at 4500 m (80 ±
10 beats/min, P < .05), and decreased at baseline 2 (64 ± 8
beats/min). No significant changes were found for systolic
and diastolic arterial blood pressure, which averaged 116 ±
8 mm Hg and 66 ± 8 mm Hg, respectively, at all altitudes
(Figure 1). No significant ST-segment depression and no
arrhythmia were found in any subject.
Respiratory Reactions
PEtCO2 was 39 ± 3 mm Hg at baseline 1 and
remained unchanged at 2000 m (38 ± 4 mm Hg); it
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decreased significantly at 4500 m (34 ± 4 mm Hg, P <
.05 vs baseline 1). SaO2 decreased from 97% ± 1% at
baseline 1 to 94% ± 2% at 2000 m (P < .05) and 83% ±
4% at 4500 m (P < .0001). The respiratory frequency was
about 14 ± 3 breaths/min and remained constant.
Myocardial Blood Flow
Estimates of mean MBF were 0.97 ± 0.21 mL/min/g
at baseline 1 (Zurich, 450 m), 1.07 ± 0.30 mL/min/g at
2000 m (not significant [NS]), 1.56 ± 0.36 mL/min/g at
4500 m (P < .0001 vs baseline 1 and vs 2000 m), and
1.07 ± 0.20 mL/min/g at baseline 2 (Table 1). Thus there
was no significant change in MBF at 2000 m (increase of
10%, NS). In contrast, MBF increased significantly by
62% at 4500 m (P < .001) and decreased at baseline 2
(Figure 2). After normalization for the RPP, MBF aver-
aged 1.34 ± 0.44 mL/min/g at baseline 1, 1.34 ± 0.39
mL/min/g at 2000 m, 1.74 ± 0.48 mL/min/g at 4500 m 
(P < .01 vs baseline 1 and 2000 m), and 1.43 ± 0.49
Figure 1. Hemodynamics and SaO2/PEtCO2. Although no significant changes were found for systolic and diastolic arte-
rial blood pressure, heart rate increased significantly at 4500 m and was normalized after return to baseline. PEtCO2 was
similar at baseline and at 2000 m but decreased significantly at 4500 m. SaO2 decreased slightly at 2000 and 4500 m and
was normalized after return to baseline. sys, Systolic; dia, diastolic; BP, blood pressure; HR, heart rate.
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mL/min/g at baseline 2 (NS vs baseline 1). Thus, even
after normalization of MBF for workload (ie, RPP),
there was a significant increase in MBF at 4500 m (36%,
P < .05) in excess of the increase in myocardial oxygen
(Figure 2). In fact, the percentage increase in MBF at
4500 m was greater than the percentage increase in RPP
(62% vs 18%, P < .005). MBF was inversely correlated
with SaO2 (r = –0.722, P < .0001), an extrapolated index
of arteriolar PO2, but not with PEtCO2 (Figure 3).
DISCUSSION
In this study the changes in MBF during high-alti-
tude exposure were assessed noninvasively by PET. In
agreement with the findings of Grubbstrom et al24 and
Kaijser et al,18 our results show that there are no signifi-
cant changes in MBF in healthy human beings at a mod-
erate altitude of 2000 m. This may explain the fact that
even patients with CAD and impaired left ventricular
function tolerate these conditions well,25 because no
sizeable flow reserve seems to be required to meet the
myocardial oxygen demand during the slight decrease in
PO2 at 2000 m. However, at high altitudes such as 4500
m, an increase in MBF of 62% is observed despite the
concomitant decrease in PEtCO2. A hypoxia-induced
increase in heart rate due to sympathetic activation and
vagal withdrawal could increase myocardial oxygen con-
sumption because of an increase in cardiac work26 and
thus could also account for increased MBF.27 There was
still a significant increase in MBF (36%, P < .05), how-
Figure 3. MBF was inversely correlated with SaO2 (an index of arteriolar PO2) (A) but not with PEtCO2 (B), supporting
the theory that diminished oxygen tension may be the main stimulus for coronary dilation and that carbon dioxide plays
a minor role at this altitude.
Figure 2. Influence of altitude on MBF. MBF did not change significantly at 2000 m but increased by 62% at 4500 m (P <
.001) and decreased at baseline 2. After normalization for RPP, there was still a significant increase in blood flow (baseline
MBF normalized [MBFnorm] 36%, P < .05), indicating that the correlation between MBF and RPP does not hold at these
conditions. This suggests that an important part of the MBF increase is due to direct hypoxia-induced vascular dilation.
A B
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ever, even after we accounted for the hypoxia-induced
increase in workload by normalizing for RPP. This sug-
gests that an important part of the MBF increase is due to
direct, hypoxia-induced dilation. In fact, MBF was
inversely correlated with SaO2 (an extrapolated index of
PaO2) but not with PEtCO2 (Figure 3). This is in agree-
ment with findings in experimental animals showing that
diminished oxygen tension in the myocardium may be
the main stimulus for coronary dilation28 and that carbon
dioxide only plays a minor role at this altitude.27 The lack
of significance in the MBF increase at 2000 m, with a
significant but slight decrease in SaO2, does not necessar-
ily imply an increase in the oxygen extraction ratio.
According to our findings, the decreasing arterial oxygen
supply seems to be met by an autoregulatory increase of
coronary flow, but the correlation between MBF and RPP
no longer holds true under these conditions. In fact, this
study, using a noninvasive technique, is the first full
report describing an increase in MBF in human beings
during acute hypoxic hypoxia, providing evidence for the
assumed mechanism of coronary autoregulation. The
exact nature of the coronary autoregulatory mechanism
remains unclear because MBF is influenced by many fac-
tors.29 For example, chemoreceptor stimulation with neu-
rogenic vasodilation mediated through vagal efferent
fibers may occur during acute hypoxia.30
The oxygen deprivation at high altitudes can be toler-
ated only because of the increase in ventilation, which
defends the alveolar PO2 against the reduced PIO2. In agree-
ment with previous findings31 the respiratory frequency
remained unchanged during our experiment, indicating that
the hyperventilation was due to an increase in tidal volume.
Initially, the hyperventilation results in a low arterial PCO2,
causing respiratory alkalosis. This increases the oxygen
affinity of hemoglobin and accelerates the oxygen loading
of the pulmonary capillary blood. Stamler et al32 recently
found that deoxygenation induces an allosteric transition in
S-nitrosohemoglobin, causing the release of a nitric oxide
group, which relaxes the vessels to bring local blood flow
in line with oxygen requirements. This mechanism could
contribute to the MBF regulation. Furthermore, adenosine
may play an important role in this context because, in vitro,
its production is linked to myocardial PO233,34 and the
major stimulus for adenosine formation seems to be an
imbalance between oxygen delivery and oxygen
demand.35,36 Cardiac adenosine production has been
reported in myocytes37 and in endothelial cells,33,37,38 and
coronary as well as myocardial adenosine receptors have
been isolated in vitro.39 This endothelium-mediated mech-
anism is potentially susceptible to harm by risk factors such
as hypertension40 and hypercholesterolemia,41 which have
been shown to cause endothelial dysfunction, even in the
absence of angiographically detectable CAD. Future stud-
ies on the influence of hypoxia in these patients and those
with CAD should provide more insight.
Study Limitations
Realignment to the transmission image to correct for
subject motion, as reported by Hoh et al,42 was not per-
formed. However, during MBF measurements at rest, lit-
tle if any subject movement occurs43 because subject
motion is most often due to side effects of potent
vasodilators such as adenosine or dipyridamole, neither
of which was used in this study. Furthermore, the sub-
jects were fixed with thoracic elastic bands after they
were placed in the PET scanner. 
Irritation caused by breathing through the mouth-
piece might have influenced the subjects’ respiration,
leading to an altered pattern of breathing and possible
Table 1. Myocardial blood flow (milliliters per minute per gram of tissue)
Volunteer Baseline1 2000 m
No. Baseline 1 normalized 2000 m normalized 4500 m
1 1.19 1.30 1.41 1.53 2.02
2 1.10 1.33 1.13 1.14 1.32
3 1.12 2.22 1.24 1.70 1.87
4 0.94 1.17 1.13 1.34 1.39
5 1.19 1.71 1.41 2.01 2.02
6 0.72 0.88 0.62 1.00 1.11
7 0.73 1.13 0.79 1.14 1.37
8 0.76 0.94 0.79 0.86 1.37
Mean ± SD 0.97 ± 0.21 1.34 ± 0.44 1.07 ± 0.30 1.34 ± 0.39 1.56 ± 0.36
Values are normalized for RPP, an index for workload.
sympathetic activation due to discomfort. To minimize
this effect, all measurements, including both baseline
measurements, were performed in the same way (the
mouthpiece and the noseclip in place). A habituation
effect over the study time that could affect the repro-
ducibility of repeated measures can most likely be
excluded because no differences were found between
baseline 1 and baseline 2 with regard to MBF, PEtCO2,
and SaO2.
The age range of the study population was lower
than that of the typical CAD age group. However, no
difference in the physiologic response to hypoxia over
a wide age range from 8 to 83 years has been
reported.44
No additional measurements were performed dur-
ing hyperemia to assess flow reserve (hyperemic/base-
line flow) because of ethical reasons (restricted amount
of radioactivity). Thus no firm conclusion on the influ-
ence of hyperemia on the myocardial flow reserve can
be drawn. However, there is no evidence to suggest that
hypoxia would affect the ceiling of maximal hyperemic
MBF usually achieved by vasodilators such as adeno-
sine or dipyridamole. This leads to the conclusion that,
in hypoxia, flow reserve might be reduced because
basal MBF is increased with no change in maximal
MBF.
Conclusions
Acute exposure to an altitude of 2000 m (corre-
sponding to the cabin pressure in most airplanes during
flight) induces no changes in MBF at rest. This might
explain why these conditions are clinically well toler-
ated, even by patients with reduced coronary flow
reserve, such as those with CAD. However, at an alti-
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tude of 4500 m, MBF increases significantly at rest,
suggesting that patients with reduced flow reserve as
seen in CAD can generally travel safely to moderate
altitudes but should avoid exposure to higher altitudes.
Although the exact mechanism of the coronary autoreg-
ulation remains unclear, adenosine is likely to play an
important role.
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